Introduction
============

Head and neck cancer (HNC) includes carcinomas of the oral cavity, pharynx, and larynx. It is the sixth most frequent cancer worldwide ([@b10-gmb-34-1-533]), amounting to half a million diagnosed cases every year ([@b13-gmb-34-1-533]). HNC represents 40.1% of all cancers registered ([@b19-gmb-34-1-533]) and is the second most prevalent in the Pakistani population ([@b15-gmb-34-1-533]).

Many environmental factors, including smoking and alcohol consumption, as well as genetic factors, are responsible for the development of HNC. Tobacco addiction is an important and strong risk factor associated with HNC ([@b21-gmb-34-1-533]), however the majority of tobacco-addicted individuals do not develop this type of cancer ([@b17-gmb-34-1-533]). The reason for this contrast is probably the fact that both exogenous exposure and genetic predisposition are involved in the development of HNC ([@b20-gmb-34-1-533]; [@b10-gmb-34-1-533]).

Polymorphisms in the carcinogen-detoxifying genes may increase or decrease carcinogen activation or detoxification, with a consequent variation in cancer risk ([@b9-gmb-34-1-533]; [@b10-gmb-34-1-533]). Most of the carcinogenic moieties are metabolically processed by xenobiotic-metabolizing enzymes in two broad steps: phase I, mediated by cytochrome p450s (CYPs), and phase II, catalyzed by glutathione S-transferases (GSTs). Phase I reactions expose functional groups of the substrates and therefore yield highly reactive intermediates. These intermediates form the substrates for phase II reactions, which involves their elimination. Hence, the coordinated expression and regulation of phase I and II enzymes determine the outcome of carcinogen exposure. Sequence variations or polymorphisms in these genes can alter the expression, function and activity of these enzymes and, consequently, the cancer risks ([@b12-gmb-34-1-533]).

Cytochromes P-450 (phase I enzyme) that are known to exhibit polymorphism include CYP1A1, CYP1B1 ([@b8-gmb-34-1-533]; [@b2-gmb-34-1-533]), CYP2A6, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 ([@b2-gmb-34-1-533]). Polymorphism of the *CYP1A1* gene has been studied most extensively in relation to HNC ([@b29-gmb-34-1-533]). It is located on chromosome 15q22-24 and encodes an aromatic hydrocarbon hydroxylase that converts PAHs to carcinogen and is predominantly expressed in extra-hepatic tissues ([@b8-gmb-34-1-533]). Its polymorphisms have been shown to increase the microsomal catalytic activity for activating pro-carcinogens ([@b4-gmb-34-1-533]).

*GSTP1* is located on chromosome 11q13 and encodes one of the phase II detoxifying enzymes. GSTP1 catalyse the conjugation of glutathione (GSH) to toxic compounds, resulting in more water-soluble and less biologically active products that are easily excreted. To date, two polymorphic alleles are known for *GSTP1*, *GSTP1*\*B and *GSTP1*\*C, in addition to the wild-type allele, *GSTP*\*A ([@b1-gmb-34-1-533]). Both alleles present an A-to-G transition at nucleotide 313 (codon 104), causing an isoleucine-to-valine change. The *GSTP1*\*C allele presents a C-to-T transition at nucleotide 341 (codon 113), in addition to the substitution at nucleotide 313, that changes alanine to valine. These two GSTP1 proteins differ in specific activity, affinity for electrophilic substrates and heat stability ([@b1-gmb-34-1-533] [@b32-gmb-34-1-533]).

These gene polymorphisms show different trends in different ethnic groups and have been found to be common in South East Asia ([@b21-gmb-34-1-533]; [@b10-gmb-34-1-533]). The current study was designed to search for *CYP1A1* and *GSTP1*gene polymorphisms in a Pakistani sample.

Material and Methods
====================

The present case-control study consisted of 388 cases with pathologically confirmed head and neck cancer and 150 cancer-free healthy individuals, matched for age and gender, as controls. They were all recruited from the National Oncology and Radiotherapy Institute (NORI) and the Institute of Medical Sciences (PIMS), Pakistan, from March 2008 to September 2009, with prior approval from the Ethics Committees of both the CIIT and the hospitals. All study subjects participated on a volunteer basis, with informed consent. All subjects were personally interviewed according to a structured questionnaire.

Blood from the subjects was sampled before starting therapy. Blood samples were collected in EDTA-containing tubes and stored at 20 °C until further use. DNA was isolated using an organic protocol with phenol-chloroform extraction, as previously described ([@b3-gmb-34-1-533]; [@b30-gmb-34-1-533]). The isolated DNA was electrophoresed on 1% ethidium-bromide-stained agarose gel, and photographed (BioDocAnalyze Biometra). Dilutions of 5 ng were made of each isolated DNA and stored at 4 °C until further use.

Primers for all exons of *CYP1A1* and *GSTP1* were synthesized by using the primer 3 input software version 0.4.0 and BLAST using NCBI PRIMER BLAST ([Table 1](#t1-gmb-34-1-533){ref-type="table"}). 2 μL of DNA (10 ng/μL) were added to a 20 μL PCR reaction mixture composed of 2 μL PCR buffer, 2 μL of each primer (10 mM), 0.24 μL deoxynucleotide triphosphate (25 mM) and 0.2 μL Taq polymerase (5u/μL). The reaction mixture was then placed in a 9700 ABI Systems thermal cycler for 5 min at 94 °C and subjected to 30 cycles at 94 °C for 25 s, annealing temperature for 1 min, and 72 °C for 1 min, followed by a final step at 72 °C for 10 min, and held at 4 °C. In order to avoid any false-positive alteration, a proofreading polymerase reaction was also performed in this regard.

Amplification products were resolved on 2% ethidium bromide-stained agarose gel, along with a 100 bp DNA ladder. All gel electrophoresis photographs were analyzed by two technicians blind to each other's assessments.

The PCR product was submitted to single-strand conformational polymorphism (SSCP) analysis, according to the procedure described by [@b28-gmb-34-1-533] and [@b24-gmb-34-1-533]. After ethidium bromide staining, the SSCP results were analyzed with a gel documentation system (BioDocAnalyze Biometra) and photographed. The samples showing mobility shifts were sequenced.

Forty-eight samples were screened based on SSCP analysis and sequenced by Macrogen (Korea) using forward and reverse primers. The reverse-primer-sequenced results were made forward-complementary and analyzed using BioEdit v 7.0.5 software. The reference sequences for *CYP1A1* (MIM ID-108330 and NG_008431.1) and *GSTP1* (MIM ID-134660 and NG_012075.1) were obtained from NCBI. Statistical analysis was performed by using the SPSS statistics 17.0 software and GraphPad Prism 5 Demo for calculating odd ratios, with a 95% confidence interval.

Results
=======

No previously reported polymorphisms of the *CYP1A1* gene were found in the present study. Instead, a novel frameshift mutation due to thymidine insertion (g.2842_2843insT) was found ([Figure 1](#f1-gmb-34-1-533){ref-type="fig"}). A significant number of patients had a mutation in exon 2 of the *CYP1A1* gene, not observed in any of the controls. Due to this mutation, the conserved core structure was altered, which disturbs the proper folding and heme-binding ability of the cytochrome P450 molecules. This frameshift mutation causes a change in the subsequent 495 nucleotide sequence, altering the protein structure of the *CYP1A1* gene. The mean age of patients showing the frameshift mutation was 51.75 (±15.7) years and 62% were males ([Table 2](#t2-gmb-34-1-533){ref-type="table"}).

Thirty-seven SSCP variants for *GSTP1* exon 7 were sequenced ([Figure 2](#f2-gmb-34-1-533){ref-type="fig"}). A significant number (p \< 0.001) of patients had substitution mutations of g.2848A \> T and g.2849G \> A in exon 7 of the *GSTP1* gene ([Figure 3](#f3-gmb-34-1-533){ref-type="fig"}). The g.2848A \> T mutation causes a sense mutation, changing the amino acid coding sequence from CUU to CUA at codon 166. Both the amino acid sequences CUU and CUA code for leucine. However, at codon 167, g.2849G \> A causes a missense mutation, resulting in the change of the amino-acid-coding sequence from GCC to ACC. GCC codes for alanine, while ACC codes for threonine. These substitution mutations are located in the C-terminal region of the *GSTP1* gene. These mutations were observed in a statistically significant (OR 2.08, 95% CI 0.97--4.45) number of male patients. Cancer of the oral cavity was found to be the most prevalent (p \< 0.05, OR 3.4, 95% CI 1.3--8.8) in these patients ([Table 2](#t2-gmb-34-1-533){ref-type="table"}). These mutations were not observed in any of the healthy controls.

The results of exon 4 and 5 sequencing, along with intron-exon junctions, showed cytosine deletions. These deletions were located in introns 3 and 4, and were found in 2.08% of the patients ([Figure 3](#f3-gmb-34-1-533){ref-type="fig"}). Intronic deletions (g.1074delC and g.1466delC) were found in a statistically significant (p \< 0.05) number of patients and in none of the controls. The mean age of patients showing these deletions was 48.18 (± 11.8) years, and a significant (p \< 0.05, OR 4.5, 95% CI 0.94--21.53) number of patients were male and had cancer of the oral cavity (OR 20.25, 95% CI 2.32--176.8) ([Table 2](#t2-gmb-34-1-533){ref-type="table"}).

Discussion
==========

In an earlier study, 13 nucleotide polymorphisms (at 12 positions: 3229, 3219, 134, 1636, 2414, 2453, 2455, 2461, 2500, 2546, 3205, and 3801) and one frameshift mutation due to a single-base insertion between 2346 and 2347 in *CYP1A1* have been reported in the Korean population ([@b12-gmb-34-1-533]). Among these, nine polymorphisms were associated with amino acid substitutions ([@b26-gmb-34-1-533]; [@b16-gmb-34-1-533]; [@b8-gmb-34-1-533]; [@b4-gmb-34-1-533]; [@b25-gmb-34-1-533]; [@b5-gmb-34-1-533]; [@b23-gmb-34-1-533]). Insertion mutations of 33 nucleotide sequences causing frameshift mutations in *CYP1A1* have also been found ([@b31-gmb-34-1-533]). The population frequencies of the various *CYP1A1* polymorphisms follow diverse ethnic and/or geographic patterns ([@b14-gmb-34-1-533]).

In the present study, none of the so far reported variants of the *CYP1A1* gene were observed in the Pakistani population. Instead, a novel frameshift mutation (g.2842_2843insT) affecting 495 nucleotide sequences was observed in the studied patients. Due to this mutation, all the amino acids subsequent to the insertion were changed and the protein structure was altered, leading to an altered protein expression.

Similar to *CYP1A1*, no previously reported variants were found for the *GSTP1* gene. These results are different from most of the studies in the literature ([@b9-gmb-34-1-533]; [@b6-gmb-34-1-533]; [@b20-gmb-34-1-533]). A possible reason for this may be the variation in *GSTP1* polymorphisms in different populations. [@b18-gmb-34-1-533] found 35 SNPs in four ethnic groups in America, and 17 of these SNPs were novel mutations.

This study is the first to report four novel mutations in the *GSTP1* gene in the Pakistani population. Two silent mutations with intronic deletions of C, one exonic non-synonymous and one synonymous substitution mutations altering *GSTP1* mRNA expression were found. The exonic substitutions result in leucine-to-leucine formation and a nonsynonymous alanine-to-threonine. These two exonic mutations are located at codon 166 and 167, and they are in the GST motif II (α 6 helix residues 150--167 and the preceding loop residues 137--149). GST motif II contains the "hydrophobic staple" made up of Ile149 and Tyr154, necessary for GST folding ([@b11-gmb-34-1-533]); mutations in this motif have been shown to affect folding and refolding pathways of the enzymes ([@b11-gmb-34-1-533]; [@b7-gmb-34-1-533] [@b22-gmb-34-1-533]; [@b27-gmb-34-1-533]). It is hypothesized that the GST motif II is involved in the nucleation mechanism of the protein and that the substitution of alanine by threonine may alter this transient substructure. The current mutation causes a change in the C-terminal protein domain, altering the functional activity of GSTP1. Mechanistically, two single nucleotide polymorphisms in the intronic region of the *GSTP1* gene may either result in differential binding of putative regulatory proteins, or it may be in linkage disequilibrium with other mutations affecting GSTP1 inducibility.

In conclusion, mutations in genes *CYP1A1* and *GSTP1* were found to be significantly higher in Pakistani patients with HNC compared to healthy controls. However, to determine the role of these genetic changes in increasing the cancer risk, an integrated analysis of many genes involved in cancer development is required. The identification of mutations in genes associated with the xenobiotic metabolism may provide a basis for understanding the high degree of individual variability in the susceptibility to the adverse effects of environmental substances.
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![Substitution mutations of A to T and G to A at positions 2848 and 2849 of the *GSTP1* gene, respectively, in HNC patients.](gmb-34-1-533-gfig2){#f2-gmb-34-1-533}

![Sequencing results showing deletion of C between C and A in intron 3 at position 1074 (a) and deletion of C in intron 4 of the *GSTP1* gene (b) in HNC patients.](gmb-34-1-533-gfig3){#f3-gmb-34-1-533}

###### 

Primer sequences used in PCR SSCP for *GSTP1* and *CYP1A1*.

                  Exons                    Primer Sequences (5′-3′)   Product size (bp)
  --------------- ------------------------ -------------------------- -------------------
  *CYP1A1* gene   Exon1F                   GGTTGTGATTAGTTCTTTGG       459
  Exon1R          GTGTTGAAAAGGAGAGGAGT                                
  Exon2aF         GAATGAAATGGAGTTGGATT     381                        
  Exon2aR         AGGATCGTATTCTCTGCTGT                                
  Exon2bF         AGAACCAAGGCTCCATAAT      476                        
  Exon2bR         ATTGCATGAATGTGGTTAGA                                
  Exon3F          CCTTCTCTCCATTCCCCTGT     150                        
  Exon3R          GTAAGACAAAGGCTGGTGCTG                               
  Exon4F          GCCTGGGTTAAGTATGCAGAT    154                        
  Exon4R          CTGACAGGGCACCCAATACT                                
  Exon5F          TGACACTTTGAATGCTCTTTCC   154                        
  Exon5R          AAACCAAACCCATGCAAAAG                                
  Exon6F          AGGACCCTGGAGTCGATTG      163                        
  Exon6R          AGCTCCTGGCACTGGTAGAG                                
  Exon 7aF        GCATTGATCCTCCTGTCCAT     594                        
  Exon 7aR        CAGAGGCAAGTCCAGGGTAG                                
  Exon 7bF        TGTCTACCTGGTCTGGTTGG     600                        
  Exon 7bR        CCTCCAGGACAGCAATAAGG                                
  Exon 7cF        CTGCCAAGAGTGAAGGGAAG     590                        
  Exon 7cR        AACACAGAATGGGGTTCAGG                                
  Exon1F          AGTTCGCTGCGCACACTT       465                        
  Exon1R          GACGTCCTGGGTCCCCTA                                  
  Exon2F          GTCCCCAGTGCCGTTAGC       277                        
  Exon2R          GATAAGGGGGTTCGGATCTC                                
  Exon3F          GGAGGAACCTGTTTCCCTGT     277                        
  Exon3R          GTCCCCCGATCCTAGTCAC                                 
                                                                      
  *GSTP1* gene    Exon4F                   GGGGCTGTGACTAGGATCG        237
  Exon4R          GGGCAGCTGATTTAAACAAAA                               
  Exon5F          ACAGACAGCCCCCTGGTT       227                        
  Exon5R          AAGCCACCTGAGGGGTAAG                                 
  Exon6F          GCAAGCAGAGGAGAATCTGG     278                        
  Exon6R          GCTAAACAAATGGCTCACACC                               
  Exon7F          AGACCTAGGGGATGGGCTTA     451                        
  Exon7R          GTGCTGGAGGAGCTGTTTTC                                

###### 

Statistical evaluation of frameshift mutation in gene *CYP1A1* and exonic and intronic mutations in gene *GSTP1* in HNC patients

                       *CYP1A1* mutation   *GSTP1* substitution mutation   *GSTP1* intronic variation                                       
  -------------------- ------------------- ------------------------------- ---------------------------- -------------------- -------------- ---------------------
  Total of patients    21                  9.4 (1.3--70.8)                 9.50%                        15.7 (2.14--115.5)   2.80%          4.3 (0.56--34)
                                                                                                                                            
  Gender                                                                                                                                    
                                                                                                                                            
  Female               62%                 1.6 (0.09--29.8)                32.40%                       0.48 (0.22--1.03)    18.20%         0.22 (0.22--1.03)
  Male                 38%                 0.6 (0.03--11.3)                67.60%                       2.08 (0.97--4.45)    81.80%         4.5 (0.94--21.53)
                                                                                                                                            
  Age (years)                                                                                                                               
                                                                                                                                            
  Mean                 51.75 ± 15.7                                        46.2 ± 15.6                                       48.18 ± 11.8   
  \< 48                52%                 1.1 (0.06--20.0)                45.90%                       0.85 (0.41--1.75)    45.50%         0.83 (0.424--2.85)
  \> 48                48%                 0.9 (0.05--16.5)                54.10%                       1.17 (0.57--2.42)    54.50%         1.2 (0.35--4.1)
                                                                                                                                            
  Smoking                                                                                                                                   
                                                                                                                                            
  Yes                  62%                 1.6 (0.09--29.8)                64.90%                       1.85 (0.87--3.89)    63.60%         1.75 (0.49--6.22)
  No                   38%                 0.6 (0.03--11.3)                35.10%                       0.54 (0.26--1.14)    36.40%         0.57 (0.16--2.03)
                                                                                                                                            
  Occupation                                                                                                                                
                                                                                                                                            
  Job                  9                   0.75 (0.04--13.7)               35.10%                       0.3 (0.13--0.76)     45.50%         0.69 (0.13--3.72)
  Jobless              8                   0.62 (0.03--11.3)               35.10%                       0.3 (0.13--0.76)     18.20%         0.05 (0.006--0.43)
  House- wife          4                   0.2 (0.01--4.62)                29.80%                       0.18 (0.07--0.49)    36.30%         0.33 (0.06--1.86)
                                                                                                                                            
  Location of Cancer                                                                                                                        
                                                                                                                                            
  Oral cavity          76%                 3.2 (0.17--61.02)               64.90%                       3.4 (1.3--8.8)       81.80%         20.25 (2.32--176.8)
  Pharynx              14%                 0.17 (0.01--3.4)                18.90%                       0.05 (0.02--0.2)     9.10%          0.01 (0.0005--0.18)
  Larynx               10%                 0.11 (0.005--2.4)               16.20%                       0.03 (0.02--0.13)    9.10%          0.01 (0.0005--0.18)
